Medicines (Sep 2021)

Autoimmune Disorders & COVID-19

  • Leonardo Freire-de-Lima,
  • Aline Miranda Scovino,
  • Camilla Cristie Barreto Menezes,
  • Leonardo Marques da Fonseca,
  • Jhenifer Santos dos Reis,
  • Marcos André Rodrigues da Costa Santos,
  • Kelli Monteiro da Costa,
  • Carlos Antonio do Nascimento Santos,
  • Celio Geraldo Freire-de-Lima,
  • Alexandre Morrot

DOI
https://doi.org/10.3390/medicines8100055
Journal volume & issue
Vol. 8, no. 10
p. 55

Abstract

Read online

Coronavirus disease 2019 (COVID-19) can progress to severe pneumonia with respiratory failure and is aggravated by the deregulation of the immune system causing an excessive inflammation including the cytokine storm. Since 2019, several studies regarding the interplay between autoimmune diseases and COVID-19 infections is increasing all over the world. In addition, thanks to new scientific findings, we actually know better why certain conditions are considered a higher risk in both situations. There are instances when having an autoimmune disease increases susceptibility to COVID-19 complications, such as when autoantibodies capable of neutralizing type I IFN are present, and other situations in which having COVID-19 infection precedes the appearance of various autoimmune and autoinflammatory diseases, including multisystem inflammatory syndrome in children (MIS-C), Guillain-Barré syndrome, and Autoimmune haemolytic anaemia (AIHA), thus, adding to the growing mystery surrounding the SARS-CoV-2 virus and raising questions about the nature of its link with autoimmune and autoinflammatory sequelae. Herein, we discuss the role of host and virus genetics and some possible immunological mechanisms that might lead to the disease aggravation.

Keywords